Paclitaxel

Generic Name
Paclitaxel
Brand Names
Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin
Drug Type
Small Molecule
Chemical Formula
C47H51NO14
CAS Number
33069-62-4
Unique Ingredient Identifier
P88XT4IS4D
Background

Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication

Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions
Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer
Associated Therapies
-
Clinical Trials
Related News

A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

First Posted Date
2021-04-06
Last Posted Date
2024-11-11
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
50
Registration Number
NCT04832854
Locations
🇨🇭

Kantonsspital Winterthur; Medizinische Onkologie, Winterthur, Switzerland

🇨🇭

UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie, Zürich, Switzerland

🇦🇺

Cabrini Hospital Malvern, Malvern, Victoria, Australia

and more 21 locations

Comparative Study of Lobaplatin and Paclitaxel in Advanced Gastric Cancer Patients With D2 Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy

First Posted Date
2021-03-22
Last Posted Date
2022-02-21
Lead Sponsor
Wuhan Union Hospital, China
Target Recruit Count
231
Registration Number
NCT04808466
Locations
🇨🇳

Wuhan Union Hospital, Wuhan, Hubei, China

Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)

First Posted Date
2021-03-19
Last Posted Date
2022-06-01
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
342
Registration Number
NCT04807673
Locations
🇨🇳

Department of minimally invasive esophageal surgery, Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer

First Posted Date
2021-03-19
Last Posted Date
2022-05-05
Lead Sponsor
Shanghai Henlius Biotech
Registration Number
NCT04806945
Locations
🇨🇳

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China

Toripalimab With Paclitaxel and Cisplatin as Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma

First Posted Date
2021-03-18
Last Posted Date
2023-02-01
Lead Sponsor
Peking University
Target Recruit Count
53
Registration Number
NCT04804696
Locations
🇨🇳

Beijing Cancer Hospital / Peking University Cancer Hospital, Beijing, Beijing, China

A Study of HB002.1T Plus Chemotherapy in Subjects With Solid Tumor

First Posted Date
2021-03-17
Last Posted Date
2021-07-28
Lead Sponsor
Huabo Biopharm Co., Ltd.
Target Recruit Count
72
Registration Number
NCT04802980
Locations
🇨🇳

Shanghai East Hospital, Shanghai, Shanghai, China

Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

First Posted Date
2021-03-12
Last Posted Date
2024-11-18
Lead Sponsor
IDEAYA Biosciences
Target Recruit Count
180
Registration Number
NCT04794699
Locations
🇺🇸

Honor Health Research Institute, Scottsdale, Arizona, United States

🇺🇸

University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

🇺🇸

City of Hope, Duarte, California, United States

and more 35 locations

Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

First Posted Date
2021-03-04
Last Posted Date
2024-02-06
Lead Sponsor
Floor Backes, MD
Target Recruit Count
38
Registration Number
NCT04781088
Locations
🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

🇺🇸

Allegheny Health Network, Pittsburgh, Pennsylvania, United States

Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy with Atezolizumab - CTX Therapy

First Posted Date
2021-02-25
Last Posted Date
2024-11-04
Lead Sponsor
Palleos Healthcare GmbH
Target Recruit Count
416
Registration Number
NCT04770272
Locations
🇩🇪

Marienhospital Bottrop gGmbH; Klinik für Frauenheilkunde und Geburtshilfe;, Bottrop, Germany

MicroRNA Profiles in Triple Negative Breast Cancer

First Posted Date
2021-02-25
Last Posted Date
2022-02-18
Lead Sponsor
University College Hospital, Ibadan
Target Recruit Count
42
Registration Number
NCT04771871
Locations
🇳🇬

Lagos State University Teaching Hospital, Lagos, Nigeria

🇳🇬

Lagos University Teaching Hospital, Lagos, Nigeria

🇳🇬

Obafemi Awolowo University Teaching Hospital, Ile-Ife, Oshun, Nigeria

and more 1 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy